New Mid-Term Management Plan: Transformation 2030
Filed with TSE · · 15 pages · English
Shin Nippon Biomedical Laboratories, Ltd. on 6ix
In the deck
Earlier from Shin Nippon Biomedical Laboratories
- Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)
- Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
- Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
- Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
- 英語版 株主通信（2023/04/01~2023/09/30）を発行しました
Follow Shin Nippon Biomedical Laboratories into a list and get an email when it puts out news.
Follow Shin Nippon Biomedical Laboratories